Individually Tailored Prophylaxis in Patients With Severe Hemophilia A

NCT ID: NCT00995046

Last Updated: 2013-05-14

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-09-30

Brief Summary

Patients with severe haemophilia A lack clotting factor FVIII and suffer from spontaneous and traumatic bleeds. In the absence of treatment, frequent bleeds in joints lead to severe joint destruction. In 1960s, prophylactic therapy was developed involving the infusion of clotting factor on a regular schedule in order to keep clotting levels sufficiently high to prevent spontaneous bleeding episodes. Prophylaxis is started at an early age before the age of 2 years or after the first joint bleed. The Malmö experience indicates that treatment is most effective when administered in large doses at least 3 times weekly. However, such an intensive treatment in young boys may be very difficult to carry out for home treatment. Currently, there is no international recommendation on prophylactic therapy regimens. Because of the high cost and limited availability of factor concentrates, dosing is an important issue in prophylaxis therapy. It was recently shown that 24 hours after FVIII concentrate administration, in patients presenting similar FVIIII levels, thrombin generation capacity may be significantly different. In addition, independently of the FVIII level, a correlation was found between severe clinical bleeding phenotype and thrombin generating capacity. The aim of the present clinical study is to assess the thrombin generation test as the main surrogate marker to evaluate the coagulating capacity of haemophiliacs on prophylaxis regimen. Optimizing prophylactic therapy to patient's phenotype with no loss of clinical effectiveness can significantly improve patients' quality of life, protect haemophilic children against arthropathy and possibly limit the cost of the prophylaxis therapy.

Conditions

Hemophilia A

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: NONE

Study Groups

usual prophylaxis regimen

All patients will receive their usual prophylaxis regimen during the first 6 months

Group Type: ACTIVE_COMPARATOR

FVIII

Intervention Type: DRUG

6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.

individually tailored prophylaxis regimen

All patients will receive an individually tailored prophylaxis regimen in accordance with TGT results during the second 6 month-period.

Group Type: EXPERIMENTAL

FVIII

Intervention Type: DRUG

1 month period where thrombin generating capacity will be evaluated, followed by 6 months of "individually" tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.

Interventions

FVIII

6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.

Intervention Type: DRUG

FVIII

1 month period where thrombin generating capacity will be evaluated, followed by 6 months of "individually" tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Severe haemophilia A (FVIII < 1 IU/dl)
• Currently on prophylactic therapy administered at least 3 times per week with a clinical efficiency
• Age: 6 - 45 years
• Adequate venous access in adults and children i.e. presence of 2 or more good quality peripheral veins, in order to avoid the need for a central venous device. One peripheral vein for FVIII infusions and one other for blood sampling are required.
• Competent in home treatment and infusion therapy (patient or parents)
• Ability of patient or family (for minors) to give informed consent
• Patient affiliated to French Social Insurance System.

• Presence of a documented target joint

Exclusion Criteria

• Age < 6 years and > 45 years
• Hemophilia A with documented history of inhibitor
• Clinically symptomatic liver disease (supported by e.g. diagnosis of cirrhosis, portal hypertension, ascites, PT > 5 seconds above upper limit of normal)
• Platelet count < 100x109/l
• Planned elective surgery within 13 months

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yesim Dargaud, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospices Civils de Lyon, France

Locations

Hopital Edouard Herriot

Lyon, , France

Countries

France

Other Identifiers

2007.482

Identifier Type: -

Identifier Source: org_study_id